{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.20","value":"67.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.43","value":"-6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C2D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.50","value":"-8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.79","value":"-9.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C4D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.06","value":"-6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.07","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C6D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.26","value":"-7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C7D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.59","value":"-15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C8D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.84","value":"-4.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.29","value":"-4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C10D1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimated due to single participant.","groupId":"OG000","spread":"NA","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C11D1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimated due to single participant.","groupId":"OG000","spread":"NA","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C12D1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimated due to single participant.","groupId":"OG000","spread":"NA","value":"-23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C13D1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimated due to single participant.","groupId":"OG000","spread":"NA","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C14D1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimated due to single participant.","groupId":"OG000","spread":"NA","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C15D1"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimated due to single participant.","groupId":"OG000","spread":"NA","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C16D1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C17D1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C18D1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C19D1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Trial Outcomes Index Score: Change at C20D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"FACT-MM combines the general version of the FACT (FACT-G) with a MM-specific sub-scale (14 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI); total of 41 items) is the primary measurement of interest, comprised of the Physical and Functional sub-scales plus the MM-specific sub-scale. Each item is rated on a 5-point Likert scale, ranging from 0 (\"Not at all\") to 4 (\"Very much\"), therefore the TOI has a score ranging from 0 to 120. Higher scores indicated improvement in well being.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, selinexor 80 mg PO plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).","id":"OG000","title":"Part 2"}],"paramType":"MEAN","populationDescription":"mITT population set. Here, \"Number of participants analyzed\" signifies those participants who were evaluable for this outcome measure at given time points. Data was not planned to be collected and analyzed for Part 1.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycle 2 to Cycle 20 (up to a maximum of 17 months)","title":"Part 2: Change From Baseline in Health-related Quality of Life (HRQL) Score Based on Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) Questionnaire","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}